Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Patients previously exposed to daratumumab can successfully receive teclistamab combined with daratumumab if they have been off anti-CD38 therapy for at least a year. Faculty emphasize that this approach produces durable remissions despite limited representation in early registration trials.

Related Insights

Unlike immunotherapy, where re-challenge after progression is dubious, there is an emerging clinical practice of re-challenging patients with the same antibody-drug conjugate (ADC), such as enfortumab vedotin (EV), after a treatment break forced by toxicity. Anecdotally, patients are showing great responses, highlighting a key area for prospective data generation.

In combination with bispecifics like teclistamab, daratumumab not only targets myeloma cells but also enhances the partner drug's efficacy by reducing immunosuppressive T-regulatory (Tregs) and B-regulatory (Bregs) cells, making the primary therapy more effective.

Real-world data suggests that using one antibody-drug conjugate (ADC) immediately after another is often ineffective. A potential strategy to overcome this resistance is to administer a different class of chemotherapy before starting the second ADC.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

Despite the individual high efficacy of both BCMA-directed therapies and anti-CD38 antibodies, there is significant clinical concern about combining them. The potential for compounded immunosuppression and severe infection risk is a major barrier shaping clinical trial design and favoring sequential use over concurrent combination.

Clinicians should not be deterred from using CD19 CAR T-cell therapy in patients who have previously received other CD19-targeting agents like tafasitamab. Preclinical and retrospective clinical data suggest prior exposure does not impair CAR T efficacy, and therefore re-testing for CD19 expression is unnecessary.

The profound success of anti-CD38 antibodies like daratumumab isn't just due to their direct anti-myeloma effect. A key part of their efficacy comes from altering the tumor microenvironment by reducing immunosuppressive T-regulatory cells and expanding anti-tumor T-cell clones, creating a synergistic effect.

An expert treating DLBCL states they no longer use bispecific antibodies as monotherapy. Combining them with partners like chemotherapy (GemOx) or ADCs (Polatuzumab) raises the complete response rate by 15-20%, offering a better chance of benefit for patients.

Prior CAR T-cell therapy does not compromise the clinical efficacy of CD20 x CD3 bispecific antibodies in diffuse large B-cell lymphoma. In phase 2 trials, epcoritamab achieved a 36% complete remission rate in post-CAR T patients compared to 39% overall. Similarly, glofitumab demonstrated complete remission rates in patients with prior CAR T exposure comparable to those who were CAR T-naive, with durable remissions observed in both groups.

In cases of severe ITP unresponsive to standard therapies, the anti-CD38 monoclonal antibody daratumumab can be highly effective. It works by eliminating the long-lived plasma cells responsible for secreting platelet autoantibodies, a mechanism distinct from other ITP treatments.

Rechallenge Daratumumab Alongside Teclistamab in Patients Off Therapy for One Year | RiffOn